Arcoma AB (OSTO:ARCOMA) Cyclically Adjusted Revenue per Share: kr11.56 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ARCOMA Arcoma AB OSTO:ARCOMA
75 GF Score
Price kr7.98
GF Value kr7.91
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Arcoma AB Cyclically Adjusted Revenue per Share?

Arcoma AB OSTO:ARCOMA -3.16% 75 Cyclically Adjusted Revenue per Share is kr11.56 as of Jun. 2026. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 75/100 and a GF Value™ of kr7.91 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Arcoma AB's adjusted revenue per share for the three months ended in Jun. 2026 was kr2.208. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr11.56 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Arcoma AB's average Cyclically Adjusted Revenue Growth Rate was -4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-29), Arcoma AB's current stock price is kr7.98. Arcoma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr11.56. Arcoma AB's Cyclically Adjusted PS Ratio of today is 0.69.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arcoma AB was 0.86. The lowest was 0.13. And the median was 0.30.


Arcoma AB  (OSTO:ARCOMA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Arcoma AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.98/11.56
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arcoma AB was 0.86. The lowest was 0.13. And the median was 0.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Arcoma AB Cyclically Adjusted Revenue per Share Related Terms


Arcoma AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Arcoma AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcoma AB Cyclically Adjusted Revenue per Share Chart

Arcoma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 56.02 12.70 11.59

Arcoma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.09 11.80 11.59 11.58 11.56

OSTO:ARCOMA vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Arcoma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcoma AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arcoma AB's Cyclically Adjusted PS Ratio falls into.


OSTO:ARCOMA
75GF Score
Arcoma AB OSTO:ARCOMA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcoma AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arcoma AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.208/134.6100*134.6100
=2.208

Current CPI (Jun. 2026) = 134.6100.

Arcoma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.523 101.138 3.358
201612 3.058 102.022 4.035
201703 2.223 102.022 2.933
201706 2.591 102.752 3.394
201709 1.340 103.279 1.747
201712 1.984 103.793 2.573
201803 1.998 103.962 2.587
201806 2.443 104.875 3.136
201809 2.316 105.679 2.950
201812 2.692 105.912 3.421
201903 2.738 105.886 3.481
201906 2.679 106.742 3.378
201909 2.399 107.214 3.012
201912 2.755 107.766 3.441
202003 2.641 106.563 3.336
202006 2.495 107.498 3.124
202009 1.740 107.635 2.176
202012 2.392 108.296 2.973
202103 2.879 108.360 3.576
202106 2.750 108.928 3.398
202109 1.775 110.338 2.165
202112 1.625 112.486 1.945
202203 1.861 114.825 2.182
202206 2.362 118.384 2.686
202209 2.222 122.296 2.446
202212 3.037 126.365 3.235
202303 2.851 127.042 3.021
202306 2.900 129.407 3.017
202309 2.719 130.224 2.811
202312 3.893 131.912 3.973
202403 3.524 132.205 3.588
202406 3.159 132.716 3.204
202409 2.418 132.304 2.460
202412 2.791 132.987 2.825
202503 2.645 132.825 2.681
202506 2.380 133.699 2.396
202509 2.089 133.480 2.107
202512 2.422 133.390 2.444
202603 2.176 133.560 2.193
202606 2.208 134.610 2.208

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr11.56 mean?
Arcoma AB (OSTO:ARCOMA) has a Cyclically Adjusted Revenue per Share of kr11.56 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arcoma AB and its competitors.
Is Arcoma AB's Cyclically Adjusted Revenue per Share too high?
Arcoma AB's current Cyclically Adjusted Revenue per Share is kr11.56. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Arcoma AB's Cyclically Adjusted Revenue per Share of kr11.56 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arcoma AB and its competitors. Arcoma AB's current Cyclically Adjusted Revenue per Share is kr11.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.91, compared to a current price of kr7.98 — trading 0.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr11.56. Arcoma AB's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current Cyclically Adjusted Revenue per Share is kr11.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?

Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued. The current stock price of kr7.98 is trading 0.9% above its estimated GF Value™ of kr7.91. GuruFocus considers Arcoma AB to be Fairly Valued.

Key valuation signals for OSTO:ARCOMA:

  • Cyclically Adjusted Revenue per Share: kr11.56
  • GF Value™: kr7.91 vs. price of kr7.98 (0.9% above fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arcoma AB Business Description

Address Annavagen 1, Vaxjo, SWE, SE-352 46
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score

Get the complete analysis for OSTO:ARCOMA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.98
Price
kr7.91
GF Value